PRODUCT INFORMATION



Roxatidine-d₁₀ (hemioxalate) Item No. 34007

| CAS Registry No.: | 2832423-41-1 | |
|--|---|-----|
| Formal Name: | 2-hydroxy-N-[3-[3-(1-piperidinyl- | |
| | 2,2,3,3,4,4,5,5,6,6-d ₁₀ -methyl)phenoxy] propyl]-acetamide, ethanedioate (2:1) | р Ņ |
| MF: | $C_{17}H_{16}D_{10}N_2O_3 \bullet 1/2C_2H_2O_4$ | |
| FW: | 361.5 | |
| Chemical Purity: | ≥95% (Roxatidine) | |
| Deuterium | | D D |
| Incorporation: | ≥99% deuterated forms (d ₁ -d ₁₀); ≤1% d ₀ | |
| Supplied as: | A solid | |
| Storage: | -20°C | |
| Stability: | ≥4 years | |
| Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis. | | |

Laboratory Procedures

Roxatidine-d₁₀ (hemioxalate) is intended for use as an internal standard for the quantification of roxatidine by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated versus unlabeled).

Roxatidine-d₁₀ (hemioxalate) is supplied as a solid. A stock solution may be made by dissolving the roxatidine- d_{10} (hemioxalate) in the solvent of choice, which should be purged with an inert gas. Roxatidine- d_{10} (hemioxalate) is soluble in DMSO.

Description

Roxatidine is a histamine H₂ receptor antagonist and major active metabolite of roxatidine acetate (Item No. 21248).¹ Roxatidine reduces histamine-induced adenylate cyclase production in guinea pig parietal cells (IC₅₀ = 0.8 μ M). It inhibits histamine-induced hydrogen ion accumulation in the same cells (pA₂ = 7.03). Roxatidine (200 mg/kg) reduces small intestinal lesion area in a rat model of gastric mucosal injury induced by indomethacin (Item No. 70270).²

References

- 1. Sewing, K.-F., Beil, W., and Hannemann, H. Comparative pharmacology of histamine H2-receptor antagonists. Drugs 35(Suppl. 3), 25-29 (1988).
- 2. Umegaki, E., Yoda, Y., Tokioka, S., et al. Protective effect of roxatidine against indomethacininduced small intestinal mucosal injury in rats. J. Gastroenterol. Hepatol. 25(Suppl. 1), S35-S40 (2010).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

uyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website

Copyright Cayman Chemical Company, 09/08/223

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM